VYTRUS BIOTECH EO -01 (V5P) - Total Liabilities

Latest as of December 2025: €4.35 Million EUR ≈ $5.09 Million USD

Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) has total liabilities worth €4.35 Million EUR (≈ $5.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore VYTRUS BIOTECH EO -01 (V5P) equity growth momentum to track the company's year-over-year net asset growth rate.

VYTRUS BIOTECH EO -01 - Total Liabilities Trend (2021–2025)

This chart illustrates how VYTRUS BIOTECH EO -01's total liabilities have evolved over time, based on quarterly financial data. See VYTRUS BIOTECH EO -01 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

VYTRUS BIOTECH EO -01 Competitors by Total Liabilities

The table below lists competitors of VYTRUS BIOTECH EO -01 ranked by their total liabilities.

Company Country Total Liabilities
Business Online PCL
BK:BOL
Thailand ฿453.29 Million
Chosun Refractories Co Ltd
KO:000480
Korea ₩778.50 Billion
Sonadezi Chau Duc Shareholding Co
VN:SZC
Vietnam ₫5.11 Trillion
Shaver Shop Group Ltd
AU:SSG
Australia AU$71.65 Million
Fate Therapeutics Inc
NASDAQ:FATE
USA $109.61 Million
Lara Exploration Ltd.
V:LRA
Canada CA$266.12K
Genelux Corporation Common Stock
NASDAQ:GNLX
USA $9.45 Million
Amir Marketing and Investments in Agriculture Ltd
TA:AMRK
Israel ILA556.14 Million

Liability Composition Analysis (2021–2025)

This chart breaks down VYTRUS BIOTECH EO -01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VYTRUS BIOTECH EO -01 (V5P) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how VYTRUS BIOTECH EO -01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for VYTRUS BIOTECH EO -01 (2021–2025)

The table below shows the annual total liabilities of VYTRUS BIOTECH EO -01 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €4.35 Million
≈ $5.09 Million
+13.44%
2024-12-31 €3.84 Million
≈ $4.49 Million
-4.57%
2023-12-31 €4.02 Million
≈ $4.70 Million
+23.76%
2022-12-31 €3.25 Million
≈ $3.80 Million
+10.85%
2021-12-31 €2.93 Million
≈ $3.43 Million
--

About VYTRUS BIOTECH EO -01

F:V5P Germany Biotechnology
Market Cap
$148.51 Million
€127.03 Million EUR
Market Cap Rank
#18122 Global
#1695 in Germany
Share Price
€16.90
Change (1 day)
+3.36%
52-Week Range
€4.80 - €21.60
All Time High
€21.60
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more